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Abstract:  Human immunodeficiency virus (HIV) infection causes acquired immune 
deficiency syndrome (AIDS) and is a global public health issue. Anti-HIV therapy involving 
chemical drugs has improved the life quality of HIV/AIDS patients. However, emergence of 
HIV drug resistance, side effects and the necessity for long-term anti-HIV treatment are the 
main reasons for failure of anti-HIV therapy. Therefore, it is essential to isolate novel   
anti-HIV therapeutics from natural resources. Recently, a great deal of interest has been 
expressed regarding marine-derived anti-HIV agents such as phlorotannins, sulfated 
chitooligosaccharides, sulfated polysaccharides, lectins and bioactive peptides. This 
contribution presents an overview of anti-HIV therapeutics derived from marine resources 
and their potential application in HIV therapy. 
Keywords: anti-HIV agents; AIDS; phlorotannins; marine resources 
Abbreviations:  AIDS, acquired immune deficiency syndrome; SCOS, sulfated 
chitooligosaccharide; SPs, sulfated polysaccharides 
 
1. Introduction 
Human immunodeficiency virus type-1 (HIV-1) is the cause of acquired immune deficiency 
syndrome (AIDS), a major human viral disease with about 33.2 million people infected worldwide up to 
now [1,2]. Antiviral agents that interfere with HIV at different stages of viral replication have been 
developed [3,4]. However, failure in anti-AIDS treatment is observed due to the emergence of resistant 
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viruses, cross-resistance to drugs and cell toxicity [5,6]. Therefore, the search for potential drug 
candidates containing higher inhibitory activity against various HIV strains is increasing in the 
pharmaceutical industry. In this regard, natural bioactive compounds and their derivatives are great 
sources for the development of new generation anti-HIV therapeutics which are more effective with 
fewer side-effects [7–9]. 
In the past, the screening and development of natural products and chemically synthesized 
compounds have been developed as medication for HIV infections [10–14]. With marine species 
comprising approximately one-half of the total global biodiversity, the sea offers an enormous resource 
for novel compounds [15]. Moreover, very different kinds of substances have been procured from 
marine organisms because they are living in a very exigent, competitive and aggressive surrounding; 
very different in many aspects from the terrestrial environment, a situation that demands the production 
of quite specific and potent active molecules. The marine environment serves as a source of functional 
materials, including polyunsaturated fatty acids (PUFA), polysaccharides, minerals and vitamins,   
anti-oxidants, enzymes and bioactive peptides [16,17]. This paper focuses on anti-HIV therapeutic 
agents derived from marine resources and their potential medicine/medical application as novel 
functional ingredients in anti-HIV therapy. 
2. Potential Marine-Derived Anti-HIV Agents and Their Anti-HIV Activity 
2.1. Phlorotannins 
Phlorotannins, which have been found to exist within brown algae, are formed by the polymerization 
of phloroglucinol (1,3,5-tryhydroxybenzene) monomer units and biosynthesized through the acetate-
malonate pathway [18,19]. The phlorotannins are highly hydrophilic components with a wide range of 
molecular sizes ranging between 126 Da–650 kDa [20]. Marine brown algae accumulate a variety of 
phloroglucinol-based polyphenols, as phlorotannins of low, intermediate and high molecular weight 
containing both phenyl and phenoxy units [21,22]. Furthermore, phlorotannins consist of phloroglucinol 
units linked to each other in various ways, and are of wide occurrence amongst marine organisms, 
especially brown and red algae [21]. Based on the means of linkage, phlorotannins can be classified into 
four subclasses: fuhalols and phlorethols (phlorotannins with an ether linkage), fucols (with a phenyl 
linkage), fucophloroethols (with an ether and phenyl linkage), and eckols (with a dibenzodioxin 
linkage) [23]. Brown algae, which have a high concentration of phlorotannins (Figure 1), have been 
reported to possess anti-HIV activity (Table 1). 
For the first time, Ahn et al. [24] reported that 8,8’-bieckol and 8,4’’’-dieckol, which were isolated 
from the brown algae Ecklonia cava KJELLMAN, show an inhibitory effect on HIV-1 reverse 
transcriptase and protease. The inhibition against reverse transcriptase of 8,8’-bieckol with a biaryl 
linkage (IC50, 0.5 µM) was 10-fold higher than that of 8,4’’’-dieckol with a diphenyl ether   
linkage (IC50, 5.3 µM), although these two phlorotannis are dimers of eckol. The authors suggested that 
the steric hindrance of the hydroxyl and aryl groups near the biaryl linkage of 8,8’-bieckol caused the 
potent inhibitory activity. Moreover, 8,8’-bieckol selectively inhibited reverse transcriptase over 
protease, and the inhibitory effect was comparable to the positive control nevirapine (IC50, 0.28 µM). It 
is clear that the 8,8’-bieckol possessed higher inhibitory activity than 8,4’’’-dieckol. Therefore, they 
evaluated the molecular mechanisms of this compound against HIV-1 reverse transcriptase using a Mar. Drugs 2010, 8                 
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homopolymeric template/primer under steady-state condition. Kinetic study showed that 8,8’-bieckol 
inhibited the RNA-dependent DNA synthesis activity of HIV-1 reverse transcriptase noncompetitively 
against dUTP/dTTP with a Ki value of 0.78 µM. Meanwhile, this compound also exhibited a 
noncompetitive inhibition (Ki, 0.23 µM) with respect to a homopolymeric template/primer, (rA)n(dT)15. 
A possible suggestion for this phenomenon is that 8,8’-bieckol binds to HIV-1 reverse transcriptase 
only after the template/primer initially binds to the enzyme. The inhibitory effects of this compound 
shown in this kinetic model are consistent with non-nucleoside RT inhibitors, such as pyridinones [27], 
trovirdine [28]. As a result, 8,8’-bieckol might be considered as a new nonnucleoside HIV-1 RT 
inhibitor.  
Table 1. Inhibitory effects of phlorotannins on the HIV-1 reverse transcriptase (RT), 
integrase and protease. 
Compound 
IC50
a (µM) 
Ref. 
RT Integrase  Protease 
8,8’-bieckol 0.51    81.5  [24] 
8,4’’’-dieckol 5.31    36.9  [24] 
diphlorethohydroxycarmalol 9.1  25.2   [25] 
6,6’-bieckol 1.07      [26] 
a 50% inhibitory concentration.
 
Figure 1. Chemical structure of phlorotannins. 
 
 
In the next report, Ahn et al. [25] showed that Ishige okamurae Yendo-derived 
diphlorethohydroxycarmalol also has an inhibitory effect on HIV-1. This compound exhibited Mar. Drugs 2010, 8                 
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inhibitory effects on the HIV-1 reverse transcriptase and integrase with IC50 values of 9.1 μM and 25.2 
μM, respectively. However, diphlorethohydroxycarmalol did not show inhibitory activity against the  
HIV-1 protease. 
Furthermore, 6,6’-bieckol, one of the main phloroglucinol derivative naturally occurring in Ecklonia 
cava, has a potent inhibition against HIV-1 induced syncytia formation, lytic effects, and viral p24 
antigen production [26]. Moreover, 6,6’-bieckol selectively inhibited the activity of HIV-1 reverse 
transcriptase enzyme with an IC50 of 1.07 µM, as well as the inhibition of HIV-1 entry. In addition, it 
exhibited no cytotoxicity at a concentration where it inhibited HIV-1 replication almost completely. 
Therefore, 6,6’-bieckol can be employed for the development of new generation therapeutic agents 
against HIV. 
2.2. Chitin, Chitosan and Chitooligosaccharide Derivatives 
Chitin, a long-chain polymer of N-acetylglucosamine, is widely distributed as the principle 
component of living organisms such as insects, fungi, crustacean and invertebrates [29]. It is one of the 
most abundant polysaccharides and is usually prepared from the shells of crabs and shrimps [30]. 
Chitosan, a partially deacetylated polymer of N-acetylglucosamine, is produced commercially by 
deacetylation of chitin [31]. Chemical modification of chitin and chitosan generate new biofunctional 
materials which provide desired biological activities and physicochemical properties [32–36]. The 
sulfated chitin and chitosan (Figure 2) have a variety of biological functions, including anti-HIV-1,  
anti-oxidant, anti-microbial, blood anti-coagulant and hemagglutination inhibition activities. Moreover, 
some of these sulfated chitin and chitosan derivatives function in drug delivery, adsorption of metal 
ions, prevention of cancer metastasis, or as elicitors of resistance to late blight in potato [37–40]. 
Sosa et al. [41] report that the N-carboxymethylchitosan N,O-sulfate (NCMCS), a polysaccharide 
derived from N-carboxymethyl chitosan by a random sulfation reaction, could inhibit the propagation of 
the human immunodeficiency virus type 1 (HIV-1) in human CD4
+ cells. Furthermore, they suggested 
that this activity was due to blocking of the interactions of viral coat glycoprotein receptors to target 
proteins on lymphocytes and competitive inhibition of HIV-1 reverse transcriptase. Therefore, NCMCS 
is considered as a potent anti-infection agent, which prevents the invasion of HIV-1 through inhibiting 
viral adsorption to the CD4 receptor and reverse transcription of the viral genome. However, the 
inhibitory effect of chitin sulfates on HIV-1 infection depends significantly on the sites of sulfation 
(Table 2) [42]. A regioselective sulfation of C-2 (C-2S) and/or C-3 (C-3S) groups of chitin showed a 
much higher inhibitory effect on the infection of AIDS virus in vitro than the 6-O-sulfonated (C-6S) 
derivatives. Moreover, the product with sulfation at both 2 and 3 positions (C-2,3S) completely 
inhibited the infection of AIDS virus to T lymphocytes at a concentration of 0.28 µg/mL without 
significant cytotoxicity. These results indicate that biological activities of sulfated chitin are 
controllable by changing the position of the sulfate groups. Mar. Drugs 2010, 8                 
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Table 2. Anti-HIV-1 activity of chitin sulfates in vitro [42]. 
Compound  Mw (kDa)  EC50 
a (µg/mL)  CC50
 b (µg/mL) 
C-6S 58  57.0  >1000 
C-3S 28  9.6  >1000 
C-2,3S 16  0.28  >1000 
Curdlan sulfate  79 0.10 >1000 
a 50% effective concentration. 
b 50% cytotoxic concentration. 
Recently, many studies have developed aminoderivatized chitosans, which possess numerous 
biological activities such as anti-oxidant, anti-hypertensive, enzyme inhibition, and anti-microbial 
properties [43]. Among aminoderivatized chitosans, aminoethyl-chitosan, prepared from 50% 
deacetylated chitosan, showed activity against HIV-1 with an IC50 value of 17 µg/mL [44]. Thus, 
aminoethyl-chitosan can be used as new generation drug candidates against HIV. 
Figure 2. Chemical structure of sulfated chitin, chitosan and chitooligosaccharide. 
 
To improve the water-solubility and biological activity, chitosan also can be converted to 
chitooligosaccharides (COSs) via either chemical or enzymatic hydrolysis [45–47]. COSs and their 
derivatives are not only water-soluble [48] and have higher absorption profiles [49], but also possess 
various biological activities, such as ACE enzyme inhibition [50], anti-oxidant [51], anti-microbial [52],  
anti-cancer [53,54], immuno-stimulant [55], anti-diabetic [56], hypocholesterolemic [57],   
hypoglycemic [58], anti-Alzheimer’s [59], anti-coagulant [60] and adipogenesis inhibition [61]. In 
addition, sulfated chitooligosaccharide (SCOS), which were synthesized by a random sulfation reaction, 
have reported to possess anti-HIV activity at low molecular weight (3–5 kDa) (Figure 2) [62]. At 
nontoxic concentrations, SCOS significantly inhibited HIV-1-induced syncytia formation and lytic Mar. Drugs 2010, 8                 
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effect at EC50 values of 2.19 µg/mL and 1.43 µg/mL, respectively. As well, the production of p24 
antigen was suppressed at EC50 values of 4.33 µg/mL and 7.76 µg/mL for HIV-1RF and HIV-1Ba-L, 
respectively. Moreover, SCOS exhibited inhibitory activities on viral entry and virus-cell fusion via 
blocking the binding between HIV-1 gp120 and CD4 cell surface receptor. These observations indicate 
that SCOS might be useful as a novel candidate for the development of anti-HIV-1 agents. 
2.3. Sulfated Polysaccharides 
Sulfated polysaccharides (SPs) comprise a complex group of macro-molecules with a wide range of 
important biological activities. These polymers are chemically anionic and distributed widely not only 
in marine algae but also in animals such as mammals and invertebrates [63,64]. Marine algae are the 
most important source of non-animal SPs and the chemical structure of the polymers varies according to 
the algae species [65]. The amount of SPs in algae varies according to the divisions of marine algae, 
such as Chlorophyta (green algae), Rhodophyta (red algae) and Phaeophyta (brown algae). In recent 
years, various SPs isolated from marine algae have attracted much attention in the fields of 
biochemistry and pharmacology. They exhibit beneficial biological activities such as anti-HIV-1 [9], 
anti-adhesive [66], anti-coagulant [67], anti-cancer [68] and anti-inflammatory [69].  
Many species of marine algae contain significant quantities of complex structural SPs that have been 
shown to inhibit the replication of enveloped viruses including members of the flavivirus, togavirus, 
arenavirus, rhabdovirus, orthopoxvirus, and herpesvirus families [70]. The chemical structure, including 
the degree of sulfation, molecular weight, constituent sugars, conformation and dynamic 
stereochemistry, affect the antiviral activity of algal sulfated polysaccharides [71–73]. Moreover, SPs 
may inhibit the attachment of viruses with target molecules on the cell surface. The viral attachment 
peptides are highly conserved regions within rather variable scaffolds of viral surface glycoproteins. 
These peptides are poorly subject to alterations by the natural antigenic drift of viruses. Likewise, they 
are not expected to represent frequent sites of drug-induced resistant mutation. Therefore, SPs directed 
toward these target peptides are preferred candidates for antiviral drug development [71,74–76]. In this 
regard, marine-derived SPs are great sources for the development of a new generation of anti-HIV 
therapeutics, as reported by several studies (Table 3). A number of SPs from red algae have exhibited an 
appreciable HIV-1 inhibitory activity. The sulfated glucuronogalactan from red algae Schizymenia 
dubyi was reported to possess anti-HIV activity [77]. Bourgougnonl et al. [77] determined the antiviral 
activity with HIV-1 by measuring the protective effect of sulfated glucuronogalactan against the   
virus-induced cytopathogenicity in MT4 cells over eight days. As shown in their study, the syncitial 
formation was completely suppressed with 5 µg/mL of this polysaccharide. Furthermore, the HIV-1 
reverse transcriptase was inhibited at concentrations as low as 5 µg/mL, without cytotoxicity to MT4 
cells. They suggested that the mechanism of action of this polysaccharide in vitro can be been mainly 
attributed to the inhibition of virus-host cell attachment or an early step of HIV infection. 
In addition, sulfated galactans GFP extracted from the red algae Grateloupia filicina and GLPE 
obtained from Grateloupia longifolia also have antiretroviral activity in vitro. The sulfated galactan 
GFP has sulfate ester groups at carbon 2 and at carbon 2 and 6 for GLPE. Wang et al. [83] investigated 
the antiretroviral activity of these sulfated galactans in a model based on a primary isolate of HIV-1 and 
human peripheral blood mononuclear cells. These results showed that both GFP and GLPE had potent Mar. Drugs 2010, 8                 
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anti-HIV-1 activity when added at the time of infection and 2 h post-infection (EC50s, 0.010–0.003 µM 
and EC90s, 0.87–0.33 µM, respectively) with low cytotoxicity.  
Moreover, brown algae are also known to produce a variety of interesting SPs, which have been 
found to exhibit anti-HIV activity with different mechanisms of action.  Sulfated 
polymannuroguluronate (SPMG), a new form of sulfated polysaccharide extracted from brown algae 
with an average molecular mass of 8.0 kDa, is rich in 1,4-linked b-D-mannuronate, with an average of 
1.5 sulfates and 1.0 carboxyl groups per sugar residue [86]. The involution of marine sulfated 
polymannuroguluronate in inhibition of HIV-1 entry was reported by Meiyu et al. [80]. They indicated 
that binding of SPMG either to soluble oligomeric rgp120 or to complexed rgp120–sCD4 mainly 
resided in the V3 loop region. The V3 loop of gp120, considered as a positively charged region, was 
targeted by negatively charged polysaccharides. In addition, the pre-incubation of SPMG with rgp120 
triggered partial suppression of rgp120 binding to sCD4. Thus, they suggested that SPMG either shares 
common binding sites on gp120 with sCD4 or masks the docking sites of gp120 for sCD4. Finally, 
SPMG was shown to be less accessible for sCD4 when sCD4 was pre-combined with rgp120, though 
SPMG multivalently bound to sCD4 with relatively low affinity. However, SPMG may suppress the 
multivalent binding of rgp120 to sCD4 receptor when SPMG is added either prior to or after the 
interaction of rgp120 with sCD4. These effective suppressions indicate that SPMG endows both 
preventive and therapeutic potential on HIV-1 entry. 
Table 3. Marine SPs-derived anti-HIV agents. 
SPs   Major units  Sources  Ref. 
Sulfated glucuronogalactan  Galactose 
Red algae 
Schizymenia dubyi 
[77] 
Kakelokelose Mannose 
Pacific tunicate 
Didemnum molle 
[78] 
Sulfated β-galactan Galactose 
Clam 
Meretrix petechialis 
[79] 
Sulfated 
polymannoroguluronate 
Mannuronate Brown  algae 
[80] 
Sulfated polymannuronate  Mannuronate Brown  algae  [81] 
Naviculan 
Fucose, Xylose, Galactose, 
Mannose, Rhamnose 
Diatom 
Navicula directa 
[82] 
Sulfated galactans  Galactose, Xylose 
Red algae 
Grateloupia filicina, 
Grateloupia longifolia 
[83] 
Sulfated fucans  Fucose 
Brown algae 
Dictyota mertensii, 
Lobophora variegate, 
Fucus vesiculosus, 
Spatoglossum schro¨ederi 
[84] 
Galactofucan Fucose,  Galactose 
Brown algae 
Adenocystis utricularis 
[85] Mar. Drugs 2010, 8                 
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Fucans are a class of high molecular weight sulfated polysaccharides. They are widely distributed in 
several species of brown algae and composed of a mainly repeating chain of fucose. The sulfated fucans 
from the seaweed species Dictyota mertensii,  Lobophora variegata,  Spatoglossum schroederi and 
Fucus vesiculosus were reported to inhibit HIV reverse transcriptase (RT) by Queiroz et al. [84]. They 
have indicated that the galactofucan fraction from L. variegate, which is rich in galactose, fucose and 
glucose with a lower sulfate content, had a marked inhibitory effect on reverse transcriptase, with 94% 
inhibition for synthetic polynucleotides at a concentration of 1.0 µg/mL. On the other hand, fucan A 
from S. schroederi and D. mertensii, which contains mainly fucose with a lower sulfate level, showed a 
high inhibitory effect on RT enzyme at 1.0 mg/mL, with 99.03 and 99.3% inhibition, respectively. 
Meanwhile, fucan B from S. schroederi, which contains galactose, fucose and high sulfate level, 
showed a lower inhibitory activity (53.9%) at the same concentration. Taking another approach, the 
authors purified a fucan fraction from F. vesiculosus, a homofucan containing only sulfated fucose with 
high sulfate content, which exhibited high inhibitory activity of HIV on RT. This fraction inhibited 
98.1% of the reaction with poly(rA)-oligo(dT) at a concentration of 0.5 mg/mL. In addition, they 
modified SPs by carboxyreduction and desulfation to determine the structure-activity relationship. 
These modified conditions reduced the inhibitory activities of these polysaccharides for RT 
approximately four-fold. From these results, they have suggested that fucan activity is dependent on 
both the ionic changes and the sugar rings that act to spatially orientate the charges in a configuration 
and recognizes the enzyme, thus determining the specificity of the binding. 
In the recent study, Trinchero et al. [85] have shown that galactofucan fractions from the brown 
algae Adenocystis utricularis exhibited anti-HIV-1 activity in vitro. Among five fractions, EA1-20 and  
EC2-20 had a strong inhibitory effect on HIV-1 replication in vitro with low IC50 values (0.6 and  
0.9 µg/mL, respectively). Additionally, EA1-20 and EC2-20 displayed this capacity against wild type 
and drug-resistant HIV-1 strains. For active fractions, it was also shown that the inhibitory effect was 
not due to an inactivating effect on the viral particles but rather to a blockade of early events of viral 
replication. Based on these results, seaweed-derived SPs are regarded as good candidates for further 
studies on prevention of HIV-1 infection. 
Beside macroalgae, microalgae are also considered as sources of novel SPs. Navicula directa is a 
diatom often collected at a sluice gate of deep sea water. Naviculan, a sulfated polysaccharide isolated 
from N. directa as a novel antiviral agent, consisted of fucose, xylose, galactose, mannose, rhamnose, 
and other trace amounts of sugar moieties. Lee et al. [82] reported that naviculan possesses antiviral 
activity, including against herpes simplex viruses type 1 (HSV-1) and herpes simplex viruses type 2 
(HSV-2), displaying IC50 values of 14 µg/mL and 7.4 µg/mL, respectively. In addition, naviculan also 
showed an inhibitory effect on the formation of cell–cell fusion between HIV gp160- and   
CD4-expressing HeLa cells with an IC50 value of 53 µg/mL. From these results, it is indicated that this 
polysaccharide might act as an inhibitor for HSV and HIV-1 infection.  
For the first time, Amornrut et al. [79] isolated a new type of D-galactan sulfate from clam Meretrix 
petechialis and the anti-HIV activity of this polysaccharide has been evaluated by the inhibition of 
syncytia formation. Inhibition of υPE 16-induced syncytia formation in CD4 HeLa cells by D-galactan 
sulfate was 56% at 200 µg/mL and this inhibitory effect is comparable to the positive control dextran 
sulfate (95% at the same concentration). The inhibition of syncytia formation might be due to the 
interference of D-galactan sulfate on CD4-gp 120 binding.  Mar. Drugs 2010, 8                 
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Recent studies demonstrated that SPs could be used as a vaginal antiviral formulation without 
disturbing essential functions of the vaginal epithelial cells and normal bacterial flora. It will be a 
continuous challenge to select the most promising drug candidates among the wide array of available 
polysaccharide compounds. The numerous advantages over other classes of antiviral drugs, such as 
relatively low production costs, broad spectrum of antiviral properties, low cytotoxicity, safety,   
wide acceptability and novel modes of action, suggest that SPs are promising drug candidates in the  
near future. 
2.4. Lectins 
Lectins or carbohydrate-binding proteins are found in a variety of different species, ranging from 
prokaryotes to corals, algae, fungi, plants, invertebrates and vertebrates. They are involved in many 
biological processes, including host-pathogen interactions, cell-cell communication, induction of 
apoptosis, cancer metastasis and differentiation, targeting of cells, as well as recognizing and binding 
carbohydrates. Interestingly, lectins have the potential to block the binding of HIV to target cells, 
preventing HIV infection and dissemination [87]. Obviously, HIV-1 envelope glycoprotein gp120 is 
extensively glycosylated and contains approximately 24 potential N-linked glycosylated sites. These 
glycosylation sites are occupied with glycans that form almost 50% of the gp120 molecular weight. The 
gp120 glycans represent high-mannose, hybrid and complex classes and serve as ligands for different 
lectins [88]. The importance of gp120 glycans for the many aspects of HIV-1 infection makes them 
suitable targets for anti-HIV-1 treatment or prophylaxis [89–91]. There are several types of marine 
lectins for which anti-HIV activity has been reported (Table 4). Griffithsin (GRFT), a lectin isolated 
from the red algae Griffithsia sp, displayed potent anti-HIV activity [92]. GRFT is a completely novel 
protein with a molecular weight of 12.7 kDa. It consists of 120 usual amino acids, including one 
unusual amino acid at position 31 (151 Da). There are no cysteine residues among its 121 amino acids 
and no homology to any of the proteins or translated nucleotide sequences. Most likely, GRFT molecule 
is formed as a domain-swapped dimer in solution [92]. Mori et al. [92] determined that both native and 
recombinant GRFT potently inhibited the cytopathic effects of laboratory strains and clinical primary 
isolates of HIV-1 on T-lymphoblastic cells at concentrations as low as 0.043 µM. It was also shown to 
be active against both T-cell tropic and macrophage- tropic strains of HIV-1 at the same concentrations. 
Furthermore, GRFT blocked cell-cell fusion between chronically infected and uninfected cells at   
sub-nanomolar concentrations. In addition, it aborted the binding of CD4-dependent glycoprotein gp120 
to receptor-expressing cells in a glycosylation-dependent manner, and prevent gp120 binding to 2G12 
and 48d monoclonal antibody. Interestingly, soluble gp120 binding to GRFT was inhibited by the 
monosaccharides glucose, mannose and Glc-NAc but not by galactose, xylose, fucose, GalNAc or sialic 
acid-containing glycoproteins. The Mori et al. [92] study also indicated that GRFT may present four 
carbohydrate-binding domains, separated by three linker sequences Gly-Gly-Ser-Gly-Gly. This 
organization for this lectin could explain its unusually potent activity due to the possibility of the 
formation of multivalent bonds between GRFT and oligosaccharides on gp120. These properties make 
GRFT a promising potential candidate for development as a future pharmaceutical agent. 
In recent years, marine invertebrates are attractive as new sources of unusual lectins. CVL is a  
30 kDa β-galactose-specific lectin isolated from the marine worm Chaetopterus variopedatus [93].   Mar. Drugs 2010, 8                 
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Wang et al. [93] indicated that CVL interacts with the hydroxyl group of C-2 and C-4 in the galactose 
molecule. They also demonstrated that hydroxyl group at C-6 failed to influence binding of the 
galactose residues of glycoproteins with CVL while the hydroxyl group at C-3 appeared to be very 
significant for binding glycoproteins with the lectin. Moreover, they investigated the anti-HIV activity 
of CVL in vitro. Results showed that CVL inhibited cytopathic effect induced by HIV-1 and the 
production of viral p24 antigen at the early stage of virus replication with EC50 values of 0.0043 and 
0.057 μM, respectively. They also found that CVL could block the cell-to-cell fusion process of HIV 
infected and uninfected cells with an EC50 value of 0.073 μM. Finally, CVL was showed to abort 86% 
and 21% of HIV-1 entry into host cells at concentrations of 0.33 μM and 0.07 μM, respectively. It is 
clear that CVL isolated from the marine worm C. variopedatus could be a potential candidate to prevent 
HIV-1 entry into cells. 
Table 4. Anti-HIV activity of marine lectins. 
Species Lectin   
Carbohydrate 
specificity 
Activity EC50
a  Ref. 
Red algae 
 Griffithsia sp. 
GRFT 
Man/Glc-specific 
lectin 
Against T cell tropic 
and macrophage tropic 
strains of HIV-1 
 
Abort cell-to-cell fusion 
and transmission of 
HIV-1 infection 
Ranging from 
0.043–0.63 µM 
 
Ranging from 
0.043–0.63 µM 
 
[92] 
Marine worm 
Chaetopterus 
variopedatus 
CVL 
β-galactose-specific 
lectin 
Inhibit HIV-induced 
syncytium formation 
 
Inhibit HIV-1 p24 
production 
0.0043 µM 
 
0.057 µM 
[93] 
Marine worm 
Serpula vermicularis 
SVL 
GlcNAc-specific 
lectin 
Inhibit HIV-induced 
syncytium formation 
Inhibit HIV-1 p24 
production 
0.15 µg/mL 
 
0.23 µg/mL  [94] 
Marine mussel 
Crenomytilus grayanus 
CGL 
High affinity to the 
glycoproteins of 
mucin type 
Inhibit HIV-replication  45.7 µg/mL  [95] 
Ascidium 
Didemnum ternatanum 
DTL 
GlcNAc-specific 
lectin 
Inhibit HIV-replication  0.006 µg/mL   [95] 
Ascidium 
Didemnum ternatanum 
DTL-A 
GlcNAc/GalNAc and 
heparin-binding lectin 
Inhibit HIV-replication  0.59 µg/mL  [95] 
Marine worm 
Serpula vermicularis 
SVL-1 
Mannan-binding 
lectin 
Inhibit HIV-replication  89.1 µg/mL  [95] 
Marine worm 
Serpula vermicularis 
SVL-2 
GlcNAc-specific 
lectin 
Inhibit HIV-replication  0.23 µg/mL  [95] 
a 50% effective concentration. Mar. Drugs 2010, 8                 
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In addition, the marine worm Serpula vermicularis was also subject as a source of new lectins. SVL 
is a GlcNAc-specific lectin newly purified and characterized by Molchanova et al. [94]. This lectin is a 
homotetrameric glycoprotein in which two identical subunits are connected with disulfide bonds. It is 
mainly composed of aspartic and glutamic acids, glycine, valine and serine; with relatively lower 
content of basic amino acids and cysteine. The sequence of N-terminal amino acids of SVL was 
determined as ADTPCQMLGSRYGWR. SVL was proven to potently inhibit the production of viral 
p24 antigen and cytopathic effects induced by HIV-1 in host cells at EC50 values of 0.23 and   
0.15 μg/mL, respectively.  
Furthermore, Luk’yanov et al. [95] evaluated the anti-HIV activity of lectins isolated from marine 
invertebrates Crenomytilus grayanus, Didemnum ternatanum and Serpula vermicularis. CGL, a lectin 
isolated from C. grayanus mussel, exhibits a very high affinity to the glycoproteins of mucin type. DTL 
and DTL-A are lectins isolated from the ascidium D. ternatanum. DTL, a GlcNAc-specific lectin with a 
shorter carbohydrate-binding site, recognizes only terminal residues of GlcNAc and does not recognize 
the chitobiose core. DTL reveals N-chains of hybrid type rather than the carbohydrate chains of 
complex and highly mannose type. DTL-A, a GlcNAc/GalNAc and heparin-binding lectin, can be used 
to detect glycoproteins containing α-bound residues of GlcNAc/GalNAc and some SPs due to the 
peculiarities of its carbohydrate specificity. SVL-1 and SVL-2 are Ca
2+-independent lectins, revealed in 
the marine worm S. vermicularis. SVL-1 is a mannan-binding lectin with molecular mass of 65 kDa 
while SVL-2 is a GlcNAc-specific lectin with molecular mass of 50 kDa. Their composition consists of 
two subunits connected with each other by disulfide bonds forming a tetramer. These lectins were 
reported to exhibit anti HIV-1 activity in in vitro experiments. The DTL, DTL-A, SVL-2, and CGL 
inhibited the HIV-1 IIIB-induced syncytium formation in C8166 cells with EC50 values of 0.002, 0.36, 
0.15 and 27.88 µg/mL, respectively. Moreover, these lectins were confirmed to effectively inhibit virus 
replication and p24 antigen production at EC50 values as shown in Table 4. Among these lectins, DTL, 
DTL-A and CGL displayed activity against cellular fusion between the H9/HIV-1 chronically infected 
cells and the C8166 uninfected cells at the following concentrations (EC50): 1.37, 6.97 and 
35.12 µg/mL, respectively. According to their results, DTL may be regarded as a potential candidate for 
the development of novel antiviral agents. 
2.5. Bioactive Peptides 
Marine-derived bioactive peptides have been isolated widely by enzymatic hydrolysis of marine 
organisms [96–100]. Proteolytic enzymes derived from microbes, plants and animals can be used for the 
hydrolysis process of marine proteins to develop bioactive peptides [101]. Bioactive peptides are 
inactive within the sequence of their parent protein and can be released by enzymatic hydrolysis [102]. 
Moreover, bioactive peptides usually contain 3–20 amino acid residues, and their activities are based on 
the amino acid composition and sequence [103]. Marine-derived bioactive peptides have been shown to 
possess many physiological functions, including anti-hypertensive or angiotensin-I-converting enzyme 
inhibition [104], anti-oxidant [105,106], anti-coagulant [107,108], and anti-microbial [109,110] 
activities. Additionally, several studies have reported the anti-HIV activity of marine bioactive   
peptides (Table 5). Mar. Drugs 2010, 8                 
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Lee and Maruyama [111] considered that oyster produces antiviral and antibacterial substances for 
preventing infectious diseases. Thus, they searched for HIV-1 protease-inhibiting substances from 
oyster Crassostrea gigas. They observed and isolated two peptides, Leu-Leu-Glu-Tyr-Ser-Ile (1) and  
Leu-Leu-Glu-Tyr-Ser-Leu (2), which inhibited HIV-1 protease in thermolysin hydrolysate of oyster 
protein. The peptide 1 and 2 showed strong inhibition of HIV-1 protease at IC50 values of 20 and 15 
nM, respectively. Moreover, these peptides behaved as competitive inhibitors for HIV-1 protease with 
Ki values of 13 and 10 nM, respectively. Lee and Maruyama [111] confirmed that the presence of C-,  
N-terminal hydrophobic amino acids and the length of the amino acid sequence in these peptides are 
important for their inhibitory activity.  
Over the years, sponges have been known as a source of novel bioactive peptides. The novel and 
unique structural features of these peptidic metabolites have generated considerable interest. Cyclic 
depsipeptides isolated from a number of marine sponges have reported to be active as HIV   
inhibitors [119]. Callipeltin A, a novel antiviral cyclic depsidecapeptide from sponge of the genus 
Callipelta, contains four amino acids in the L configuration, alanine, leucine, threonine (two residues); 
one (arginine) in the D configuration; two N-methyl amino acids, N-methyl alanine and N-methyl 
glutamine; a methoxy tyrosine, a 3,4-dimethyl-L-glutamine; and a 4-amino-7-guanidino-2,3-
dihydroxypentanoic acid (AGDHE), formally derived from L-arginine [112]. Callipeltin A exhibited the 
inhibition of cytopathic effects induced by HIV-1 in CEM4 lymphocytic cell lines at an ED50 value of 
0.01 µg/mL. The general structure of callipeltin A was identified to be similar to a family of potent 
antiviral, didemnins, which support that it possesses anti-HIV activity.  
Table 5. HIV-1 inhibitory effect of marine peptides. 
Sources Peptide  name  Activity  Potency
  Ref. 
Oyster 
Crassostrea gigas 
Peptide 1 
Peptide 2 
Inhibit HIV-1 protease 
IC50: 20 nM (1) 
15 nM (2) 
[111] 
Marine sponge 
Callipelta 
Callipeltin A 
Inhibit cytopathic effects 
induced by HIV-1 
EC50: 0.01 µg/mL  [112] 
Marine sponge 
Theonella mirabilis 
Theonella swinhoei 
Papuamides A 
Papuamides B 
Inhibit HIV-1 infection  EC50: 4 ng/mL  [113] 
Marine sponge 
Sidonops microspinosa 
Microspinosamide 
Inhibit cytopathic effect 
of HIV-1 infection 
EC50: 0.2 µg/mL  [114] 
Marine sponge 
Neamphius huxleyi 
Neamphamide A  Against HIV-1 infection  EC50: 28 nM  [115] 
Marine sponge 
Siliquariaspongia mirabilis 
Mirabamide A 
Mirabamide C 
Mirabamide D 
Inhibit HIV-1 
neutralization and fusion 
IC50: 0.04 and 0.14 µM (A) 
0.14 and 1.3 µM (C) 
0.19 and 3.9 µM (D) 
 [116] 
Marine sponge 
Siliquariaspongia mirabilis 
Celebesides A 
Theopapuamide B 
Block HIV-1 entry (A) 
Neutralize HIV-1 (B) 
IC50: 1.9 µg/mL (A) 
0.8 µg/mL (B) 
[117] 
Marine sponge 
Homophymia sp 
Homophymine A  Against HIV-1 infection  IC50: 75 nM  [118] 
EC50: 50% effective concentration. 
IC50: 50% inhibitory concentration. Mar. Drugs 2010, 8                 
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Likewise, Ford et al. [113] have isolated novel cyclic depsipeptides papuamides A and B from 
sponges Theonella mirabilis and Theonella swinhoei. These peptides contain not only unusual amino 
acids, including 3,4-dimethylglutamine, β-methoxytyrosine, 3-methoxyalanine, and   
2,3-diaminobutanoic acid or 2-amino-2-butenoic acid residues, but also the first marine-derived 
peptides reported to contain 3-hydroxyleucine and homoproline residues. These peptides also contain a 
previously undescribed 2,3-dihydroxy-2,6,8-trimethyldeca-(4Z,6E)-dienoic acid moiety N-linked to a 
terminal glycine residue. Papuamides A and B were reported to block the infection of human   
T-lymphoblastoid cells by HIV-1 sub(RF) in vitro with an EC50 of approximately 4 ng/mL. The 
inhibitory activity of papuamides A was due to blockage by this peptide at the initial stage of the viral 
life cycle, but was not HIV-1 envelope glycoprotein specific [120]. At a similar concentration to 
papuamide A, papuamide B also prevents viral entry via interaction of this peptide with phospholipid 
present on the viral membrane [120]. Another anti-HIV candidate from the sponge is the 
microspinosamide, a new cyclic depsipeptide isolated from Sidonops microspinosa. This peptide 
incorporates 13 amino acid residues, and it is the first naturally occurring peptide to contain a   
β-hydroxy-p bromophenylalanine residue [114]. Rashid et al. [114] demonstrated that 
microspinosamide is capable of inhibiting the cytopathic effect of HIV-1 infection in an XTT-based in 
vitro assay with an EC50 value of approximately 0.2 µg/mL.  
In another study, Oku et al. [115] isolated a new HIV-inhibitory depsipeptide, neamphamide A, from 
the marine sponge Neamphius huxleyi. Neamphamide A contains an amino acid sequence of L-Leu,  
L-NMeGln, D-Arg, D- and L-Asn, two residues of D-allo-Thr, L-homoproline, (3S,4R)-3,4-dimethyl-L-
glutamine, β-methoxytyrosine, 4-amino-7-guanidino-2,3-dihydroxyheptanoic acid and an amide-linked 
3-hydroxy-2,4,6-trimethylheptanoic acid moiety. Neamphamide A was reported to have cytoprotective 
activity against HIV-1 infection (EC50, 28 nM). Similar to neamphamide A, mirabamides obtained from 
the marine sponge Siliquariaspongia mirabilis also potently inhibit HIV-1 fusion [116]. Among 
mirabamides, mirabamide A was found to be powerful against HIV-1 in neutralization and fusion 
assays with respective IC50 values of 40 and 140 nM, while mirabamides C and D were shown to be less 
effective (IC50 values between 140 nM and 1.3 μM for mirabamide C and 190 nM and 3.9 μM for 
mirabamide D). Further, Plaza et al. [116] confirmed that mirabamides inhibit HIV-1 at the level of 
membrane fusion, presumably through interactions with HIV-1 envelope glycoproteins. Other novel 
peptides, celebesides A and theopapuamide B, were also isolated from sponges of the same previously 
mentioned S. mirabilis [117]. Celebesides A is cyclic depsipeptide that incorporates a polyketide moiety 
and five amino acid residues, among which are the unusual amino acids phosphoserine and 3-carbamoyl 
threonine. Theopapuamide B, a undecapeptide, comprise two previously unreported amino acids,   
3-acetamido-2-aminopropanoic acid and 4-amino-2,3-dihydroxy-5-methylhexanoic acid. Celebesides A 
displayed an inhibition of HIV-1 entry with an IC50 value of 1.9 µg/mL, while theopapuamide B was 
active in the neutralization assay with an IC50 value of 0.8 µg/mL. Plaza et al. [117] indicated that the 
inhibitory activity of Celebesides A is due to the presence of a phosphoserine residue conserved in the 
above-mentioned anti-HIV peptides but absent in the inactive theopapuamide. However, this hypothesis 
was ruled out by evidence given in the study of Zampella and collaborators [118]. Zampella et al. [118] 
isolated a new anti-HIV cyclodepsipeptide, homophymine A, from the marine sponge Homophymia sp. 
This peptide contains an amide-linked 3-hydroxy-2,4,6-trimethyloctanoic acid moiety and 11 amino 
acid residues, including four unusual amino acid residues: (2S,3S,4R)-3,4-diMe-Gln, (2R,3R,4S)-4-Mar. Drugs 2010, 8                 
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amino-2,3-dihydroxy-1,7-heptandioic acid, L-ThrOMe, and (2R,3R,4R)-2-amino-3-hydroxy-4,5-
dimethylhexanoic acid. Obviously, homophymine A lacks β-methoxytyrosine residue which is replaced 
by an O-methyl threonine residue. Nevertheless, homophymine A was reported to potentially exhibit 
cytoprotective activity against HIV-1 infection with an IC50 value of 75 nM. The antiviral activity found 
in homophymine A ruled out the hypothesis that β-methoxytyrosine is essential for antiviral activity. 
3. Prospects of Marine Anti-HIV Drugs 
HIV-caused AIDS is a major health problem worldwide, especially in developing countries. The 
discovery of medicinal agents specifically capable of inhibiting HIV is urgently required to prevent 
globally widespread infection. Natural products derived from marine organisms are excellent sources 
for the effective discovery of anti-HIV agents. However, the development of marine drugs still faces 
several challenges, such as toxic side effects, large-scale production and cultivation, and drug 
resistance. As mentioned above, sponge-derived compounds were shown to exhibit strong inhibition of 
HIV entry but have toxic effects, which is an obstacle for development as commercial drugs. However, 
it is possible to solve this problem through the application of biochemical technologies. These 
techniques will allow the manipulation of naturally occurring compounds, such as removal or 
modification of toxic groups present in the compound to produce chemical derivatives that are far 
superior to the original [121]. Thus, this application will allow the production of compounds with 
reduced cytotoxicities and increased specificities.  
Another important challenge for HIV treatment is drug resistance. Nevertheless, a virus that has 
developed resistance to a particular drug may not be resistant to other naturally occurring derivatives, 
which display similar antiviral activities [122]. Therefore, the different derivatives of a common class 
compound that are synthesized by multiple organisms may be a solution for new drugs discovery. 
Furthermore, the numerous undiscovered unique metabolites in the marine environment are interesting 
sources to increase numbers of novel drugs against otherwise drug-resistant HIV strains.  
In addition, the anti-HIV compounds produced by marine organisms are often found in low natural 
abundance. Thus, it is really difficult to make a large-scale production of these compounds. One 
strategy to increase the yields of natural products consists of the identification, cloning and expression 
of genes associated with biosynthetic machineries and subsequent production of the compounds 
enzymatically in a heterologous host. This genetic approach also allows the production of novel 
metabolites via introducing novel biosynthesis genes into microorganisms, which will result in the 
synthesis of novel metabolites. 
4. Conclusion  
Recent studies have provided evidence that marine-derived anti-HIV agents may play a vital role 
against HIV. The possibilities of designing new drug candidates and pharmaceuticals to support 
reducing or regulating HIV infection related chronic malfunctions are promising. Moreover, these 
evidences suggest that due to valuable biological functions with beneficial health effects,   
marine-derived anti-HIV agents have potential as active ingredients for preparation of novel 
pharmaceutical products. Until now, most of studies on anti-HIV activity of marine-derived HIV Mar. Drugs 2010, 8                 
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inhibitors have been observed in vitro or in mouse model systems. Therefore, further research studies 
are needed in order to investigate their activities in human subjects. 
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